tyrosine kinase inhibitor

You have access
Targeted Therapy Followed by Cytotoxic Chemotherapy in Preoperative Patients With Locally Advanced Lung Adenocarcinoma
MASAYA AOKI, KAZUHIRO UEDA, TADASHI UMEHARA, GO KAMIMURA, TAKUYA TOKUNAGA, AYA HARADA-TAKEDA, KOKI MAEDA, TOSHIYUKI NAGATA, NAOYA YOKOMAKURA, KOTA KARIATSUMARI, YUTO NONAKA, NOBUHIRO IMAMURA, SHOICHIRO MORIZONO and MASAMI SATO

Anticancer Research May 2020, 40 (5) 2911-2916; DOI: https://doi.org/10.21873/anticanres.14268
You have access
Efficacy of Afatinib and Lapatinib Against HER2 Gene-amplified Trastuzumab-sensitive and -resistant Human Gastric Cancer Cells
SUSUMU NAKATA, MITSUGU FUJITA and HAYAO NAKANISHI

Anticancer Research November 2019, 39 (11) 5927-5932; DOI: https://doi.org/10.21873/anticanres.13797
You have access
Antiproliferative Effect of Lenvatinib on Human Liver Cancer Cell Lines In Vitro and In Vivo
SACHIKO OGASAWARA, YUTARO MIHARA, REIICHIRO KONDO, HIRONORI KUSANO, JUN AKIBA and HIROHISA YANO

Anticancer Research November 2019, 39 (11) 5973-5982; DOI: https://doi.org/10.21873/anticanres.13802
You have access
Neoadjuvant Tyrosine Kinase Inhibition in Locally-advanced Non-small Cell Lung Cancer: Two Cases and a Brief Literature Review
ANISH B. PARIKH, LINDSAY HAMMONS and JORGE E. GOMEZ

Anticancer Research February 2019, 39 (2) 897-902; DOI: https://doi.org/10.21873/anticanres.13191
You have access
Prognostic Significance of Pancreatic Metastases from Renal Cell Carcinoma in Patients Treated with Tyrosine Kinase Inhibitors
PAWEL CHROM, RAFAL STEC, LUBOMIR BODNAR and CEZARY SZCZYLIK

Anticancer Research January 2018, 38 (1) 359-365;
You have access
Identification of MicroRNAs Involved in Resistance to Sunitinib in Renal Cell Carcinoma Cells
NORIYA YAMAGUCHI, MITSUHIKO OSAKI, KUNISHIGE ONUMA, TETSUYA YUMIOKA, HIDETO IWAMOTO, TAKEHIRO SEJIMA, HIROYUKI KUGOH, ATSUSHI TAKENAKA and FUTOSHI OKADA

Anticancer Research June 2017, 37 (6) 2985-2992;
You have access
Increased HGF Expression Induces Resistance to c-MET Tyrosine Kinase Inhibitors in Gastric Cancer
SO YEONG AHN, JIN KIM, MIN A KIM, JIWOON CHOI and WOO HO KIM

Anticancer Research March 2017, 37 (3) 1127-1138;
You have access
Comparison of Tyrosine Kinase Inhibitor Versus Mammalian Target of Rapamycin Inhibitor as Second-line Molecular-targeted Therapy for Patients with Poor-risk Metastatic Renal Cell Carcinoma
HIDEAKI MIYAKE, SATOSHI IMAI, KEITA TAMURA, TAKAYUKI SUGIYAMA, HIROSHI FURUSE, SEIICHIRO OZONO and MASATO FUJISAWA

Anticancer Research March 2017, 37 (3) 1523-1528;
You have access
Teratogenic Effect of Radotinib: Case Report
JUYOUNG CHEON, JUNG WHAN AHN, KYUNG MIN PARK, GUISERA LEE and YUN SUNG JO

Anticancer Research December 2016, 36 (12) 6599-6601;
You have access
New Drug and Possible New Toxicity – Squamous Cell Carcinoma Following Imatinib in Patients with Gastrointestinal Stromal Tumors
FAISAL INAYAT and MUHAMMAD WASIF SAIF

Anticancer Research November 2016, 36 (11) 6201-6204;

Main menu

User menu

Search

tyrosine kinase inhibitor

Pages